Key opportunities in the Bronchiectasis clinical trials market include leveraging comprehensive data on trial distribution by region, identifying cost-effective trial locations, assessing trial ...
There were 579,475 instances of emergency hospitalisation being needed in the year to March 2025, analysis finds ...
Background Respiratory syncytial virus (RSV) causes substantial winter pressure on adult services. In the UK, RSV vaccination currently targets adults aged ≥75 years and care home residents; it ...
A surge in pneumonia hospital admissions has seen a leading charity demand greater focus on basic care provision ...
Good Housekeeping UK on MSN
From unfit ex-smoker to triathlon winner at 77 – the daily plan which transformed my fitness
Anne Dockery transformed her health to become a gold-medal winning athlete - here's the training plan she uses ...
Pharming Group has transitioned from a speculative play to a fundamentally attractive, cash-generating rare disease company.
Insmed Incorporated reported $144.6M in Q4 Brinsupri sales, 4.6% TAM penetration, and a 2026 Arikayce market trial expansion.
Claimants could qualify for a financial boost this year from the Department for Work and Pensions (DWP). The DWP has ...
The Department for Work and Pensions has published the complete list of 178 medical conditions that qualify for Personal Independence Payment worth up to £187.45 per week ...
DPP-1 inhibitors and macrolides likely reduce the frequency of exacerbations in patients with non-cystic fibrosis bronchiectasis compared with placebo, a network meta-analysis shows.
The list of new medicines recommended for approval at the October meeting of the EMA's human medicines committee includes Brinsupri, the first treatment for serious chronic lung disease non-cystic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results